StreetInsider on Canaccord: 2013 Could be Blockbuster for Amarin
More details on Canaccord's note:
"...Vascepa already has initial coverage at Cigna, Aetna and Humana, the analyst notes, with AMRN continuing to target Tier 2 coverage status.
"Humana announced Vascepa requires prior authorization for coverage, with previous treatment, intolerance, or contraindication to Lovaza and a Fibrate or Nicotinic acid. AMRN expects this standard initial prior-auth need by Humana will be removed in ~2 months (after additional talks with AMRN) and ultimately that the drug will reach tier 2 coverage. Humana represents ~ 6M covered lives. Vascepa already has Tier 3 coverage (no prior auth requirement) with Cigna and Aetna, which together represent ~18M covered lives."